PSMG3

PSMG3 (PAC3) is a dedicated assembly chaperone for the 20S proteasome that heterodimerizes with PSMG4 (PAC4) to nucleate and stabilize the α4–α5–α6 subcomplex during the earliest steps of α-ring biogenesis in the cytoplasm (PMID:17189198, PMID:30133132). The PAC3–PAC4 heterodimer acts as a molecular matchmaker: it templates correct α-subunit ordering, then dissociates before half-proteasome formation to permit β-ring assembly and subsequent maturation (PMID:17707236, PMID:31067643). High-resolution crystal and cryo-EM structures show that a flexible loop (residues 51–61) in the PAC3 homodimer undergoes conformational rearrangement upon heterodimerization and substrate engagement, and that PAC3/PAC4 release is coupled to PAC1 N-terminal tail repositioning during the transition to β-ring completion [PMID:31067643, PMID:bio_10.1101_2024.08.08.607236]. The intracellular bacterial pathogen Anaplasma phagocytophilum exploits PSMG3 via its effector AptA, which binds PSMG3 to enhance host proteasome activity, promote ubiquitin–proteasome/autophagy crosstalk, and suppress apoptosis (PMID:34126152).

1. 2006 High

   Identification of PAC3 as a proteasome-dedicated assembly factor resolved how α-ring intermediates are chaperoned: PAC3 binds α- and β-subunits during early 20S biogenesis and must dissociate before half-proteasome formation, establishing chaperone-assisted proteasome assembly as a stepwise process.

   Evidence Co-immunoprecipitation, siRNA knockdown, and sucrose gradient sedimentation in mammalian cells

   PMID:17189198

   Open questions at the time

   • Identity of obligate PAC3 binding partner not yet known
   • Structural basis of PAC3 interaction with α-subunits undefined
   • Order of individual α-subunit incorporation unclear
2. 2007 High

   Discovery that PAC3 functions as a heterodimer with PAC4, paralleling yeast Poc3/Poc4, established a conserved pairwise chaperone architecture (PAC1/2 and PAC3/4) acting at distinct stages upstream of Ump1-dependent maturation.

   Evidence Genetic epistasis in yeast poc mutants and functional complementation with mammalian PAC3/PAC4

   PMID:17707236

   Open questions at the time

   • Which specific α-subunits PAC3-PAC4 contacts was not resolved
   • Whether PAC3 homodimer has any physiological role remained open
3. 2018 High

   Defining the ordered assembly pathway showed that PAC3-PAC4 is required to nucleate an α4–α5–α6–α7 core intermediate as the first committed step, with α1, α3, and α2 added sequentially, clarifying the logic of subunit incorporation.

   Evidence Immunoprecipitation, sucrose gradients, siRNA knockdown, fluorescence microscopy in mammalian cells

   PMID:30133132

   Open questions at the time

   • Atomic contacts between PAC3-PAC4 and specific α-subunits unresolved
   • Trigger for PAC3-PAC4 dissociation unknown
4. 2018 Medium

   Development of thielocin B1-derived inhibitors selective for the PAC3 homodimer interface provided pharmacological proof that the PAC3 protein–protein interaction is druggable and structurally distinct from the PAC1/PAC2 interface.

   Evidence Chemical synthesis, in vitro PPI inhibition assay, SAR analysis, and in silico docking

   PMID:30455074

   Open questions at the time

   • No cellular activity or proteasome assembly phenotype reported for these compounds
   • Selectivity tested only against PAC1/PAC2; broader off-target profiling absent
5. 2019 High

   The 0.96-Å crystal structure of the PAC3 homodimer revealed a dynamic loop (residues 51–61) and enabled modeling of the PAC3-PAC4/α4/α5/α6 quintet, providing the first structural framework for how the heterodimer templates α-subunit arrangement.

   Evidence X-ray crystallography at atomic resolution, NMR spectroscopy, structural modeling

   PMID:31067643

   Open questions at the time

   • Experimental structure of the PAC3-PAC4 heterodimer itself not yet solved
   • Quintet complex model not validated by experimental structure determination
6. 2021 Medium

   The A. phagocytophilum effector AptA was shown to bind PSMG3 directly, hijacking proteasome assembly to enhance host UPS activity, promote autophagy, and suppress apoptosis — revealing PSMG3 as a pathogen-exploited node linking proteasome biogenesis to infection.

   Evidence Yeast two-hybrid, co-immunoprecipitation in HEK293T, proteasome activity and apoptosis assays

   PMID:34126152

   Open questions at the time

   • Mechanism by which AptA-PSMG3 binding enhances proteasome activity not defined
   • In vivo relevance during natural A. phagocytophilum infection not tested
   • Whether AptA disrupts or enhances PAC3-PAC4 heterodimer formation is unknown
7. 2024 High

   Cryo-EM of endogenously tagged human assembly intermediates captured PAC3/PAC4 bound to early α-ring subcomplexes and showed its dissociation precedes β-ring assembly; completion of the β-ring repositions K33 to trigger β-propeptide cleavage and concerted release of POMP and PAC1/PAC2, providing a near-complete structural narrative of 20S maturation.

   Evidence Cryo-EM of CRISPR-tagged endogenous chaperone complexes (preprint)

   PMID:bio_10.1101_2024.08.08.607236

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Kinetics of PAC3/PAC4 dissociation in live cells not measured
   • Whether PAC3/PAC4 release is actively regulated or occurs passively upon β-subunit binding remains unclear

• Key open questions include the precise signal that triggers PAC3-PAC4 dissociation from the α-ring, the physiological relevance of PAC3 homodimer versus heterodimer pools, and whether PSMG3 perturbation contributes to human disease through impaired proteasome biogenesis.
• No human genetic disease linked to PSMG3 loss-of-function
• Relative contribution of PAC3 homodimer versus heterodimer to assembly is undefined
• No in vivo animal model with PSMG3 ablation reported